A securities class action has been filed on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026, with investors seeking to serve as lead plaintiff required to move the Court by October 5, 2026. The complaint alleges the company misled investors about the timing of expanded CVS Caremark coverage for its epinephrine nasal spray, neffy, including statements that coverage would begin on July 1, 2026 and be in place for the summer and back-to-school allergy seasons, while allegedly omitting material facts about the rollout timeline; Holzer & Holzer later repeated the Oct. 5 deadline in an Aug. 12, 2026 reminder.